

Arvin C Dar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7333065/publications.pdf>

Version: 2024-02-01

21
papers

1,426
citations

777949

13
h-index

939365

18
g-index

24
all docs

24
docs citations

24
times ranked

3084
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding and drugging RAS: 40 years to break the tip of the iceberg. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	1
2	Conformational control and regulation of the pseudokinase KSR via small molecule binding interactions. <i>Methods in Enzymology</i> , 2022, 667, 365-402.	0.4	1
3	An Antagonist of KSR1-Driven Adaptive Resistance to Clinical RAS-MAPK Inhibitors. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
4	Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. <i>Nature Biotechnology</i> , 2022, 40, 1680-1689.	9.4	29
5	Targeting drug-resistant mutations in ALK. <i>Nature Cancer</i> , 2022, 3, 659-661.	5.7	1
6	Type II Binders Targeting the α -GLR-Out Conformation of the Pseudokinase STRAD \pm . <i>Biochemistry</i> , 2021, 60, 289-302.	1.2	6
7	Structural Insights into How Protein-Protein Interaction Modulates the Action of MEK Inhibitors. <i>Microscopy and Microanalysis</i> , 2021, 27, 1716-1718.	0.2	0
8	Ploidy Leads a Molecular Motor to Walk Different Paths to Drug Resistance. <i>Cell Chemical Biology</i> , 2020, 27, 770-772.	2.5	2
9	Structural basis for the action of the drug trametinib at KSR-bound MEK. <i>Nature</i> , 2020, 588, 509-514.	13.7	86
10	Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability*. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1630-1650.	2.5	14
11	Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1506-1519.	1.9	16
12	Integrated computational and Drosophila cancer model platform captures previously unappreciated chemicals perturbing a kinase network. <i>PLoS Computational Biology</i> , 2019, 15, e1006878.	1.5	10
13	A whole-animal platform to advance a clinical kinase inhibitor into new disease space. <i>Nature Chemical Biology</i> , 2018, 14, 291-298.	3.9	56
14	Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. <i>Nature</i> , 2016, 537, 112-116.	13.7	74
15	Endoplasmic reticulum stress-independent activation of unfolded protein response kinases by a small molecule ATP-mimic. <i>ELife</i> , 2015, 4, .	2.8	49
16	Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors. <i>Nature Communications</i> , 2014, 5, 5408.	5.8	66
17	A pickup in pseudokinase activity. <i>Biochemical Society Transactions</i> , 2013, 41, 987-994.	1.6	16
18	Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. <i>Nature</i> , 2012, 486, 80-84.	13.7	312

#	ARTICLE	IF	CITATIONS
19	A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. <i>Nature</i> , 2011, 472, 366-369.	13.7	223
20	The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling. <i>Annual Review of Biochemistry</i> , 2011, 80, 769-795.	5.0	316
21	Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation. <i>Chemistry and Biology</i> , 2008, 15, 1015-1022.	6.2	84